We start to see the licensing of CMX157 as a substantial first step toward creating a leading pipeline of targeted antiviral treatments. Along with FV-100, our drug applicant for the treatment of shingles, we are proud our pipeline consists of two Stage 2 assets now.’.. Chimerix, ContraVir collaborate to develop and commercialize antiviral medication candidate CMX157 Chimerix, Inc. a biopharmaceutical organization developing novel, oral antivirals in areas of high unmet medical need, and ContraVir Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the firms have entered into a strategic collaboration for the additional clinical development and commercialization of CMX157.With these humanized mouse versions, the biologists after that tested a number of immune suppressing molecules only or in mixture and discovered one mixture that worked flawlessly to protect cells produced from individual embryonic stem cells from immune rejection. That mixture was CTLA4-lg, an FDA-approved medication for treating arthritis rheumatoid that suppresses T-cells in charge of immune rejection, and a proteins called PD-L1 regarded as very important to inducing immune tolerance in tumors. The researchers found that the mixture of both of these molecules allowed the allogeneic cells to survive in humanized mice without triggering an immune rejection. If we communicate both molecules in cells produced from individual embryonic cells, we are able to secure these cells from the allogenic immune rejection, says Xu.